Exact Sciences announces 4Q, 2014 financial results: 6 things to know

Exact Sciences has reported its financial results for the fourth quarter of 2014 and full-year. Here are six things to know from the report.

1. The company reported $1.5 million in revenue for the fourth quarter, up from $1 million during the fourth quarter of 2013.

2. Exact Sciences' total revenues for the year were $1.8 million, down from $4.1 million in 2013.

3. The company has a net loss of $32.4 million for the fourth quarter, up from a $12.2 million loss in the same period in 2013. Overall in 2014, the company had a net loss of $100 million, up from $46.5 million in 2013.

4. Exact Sciences had $30.7 million in operating expenses in the fourth quarter, up from $13.3 million. Operating expenses for the year were $98 million, compared to $50.9 million in 2013. The increase in operating expenses was attributed to the support needed to launch Cologuard.

5. The company ended the year with cash, cash equivalents and marketable securities of $282.8 million, up from $133.3 million at the end of 2013.

6. "We are very pleased with our 2014 accomplishments and the success we're having with Cologuard in the short time since CMS's final coverage decision," said Kevin T. Conroy, the company's chairman and CEO. "More than 4,000 physicians ordered at least one test by year end and we reported over 4,000 Cologuard test results.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

ASC_GI_300x250

Featured Webinars

Featured Whitepapers

Featured Podcast